We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter's adjusted EPS beat estimates by 55.6%, while revenues rose 5% to $2.96 billion.
Broad-based gains were led by Drug Compounding, IV Solutions and Advanced Surgery demand.
Baxter raised its 2026 sales growth outlook to 3%-4% and adjusted EPS guidance to $1.95-$2.15.
Baxter International Inc. (BAX - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) from continuing operations of 56 cents, which topped the Zacks Consensus Estimate of 36 cents by 55.6%. The bottom line declined 5% from the year-ago quarter’s level.
On a GAAP basis, the company reported an EPS from continuing operations of 26 cents compared to an EPS of 24 cents in the prior-year quarter.
Shares of BAX gained 16.6% in pre-market trading. Year to date, the company’s shares have gained 29.6%, outperforming the industry’s fall of 16.1% and the broader S&P 500 Index’s increase of 6.7%.
Image Source: Zacks Investment Research
BAX's Revenue Mix Shows Broad-Based Gains
Revenues from continued operations totaled $2.96 billion, up 5% year over year on both a reported and organic basis. The top line surpassed the Zacks Consensus Estimate by 5.9%. Growth was driven by broad-based gains across Baxter’s segments and divisions.
U.S. sales from continuing operations totaled $1.59 billion, up 4% on both a reported and organic basis. International sales from continuing operations totaled $1.37 billion, reflecting an increase of 7% on a reported basis and 5% on an organic basis.
International growth outpaced the domestic business, while organic growth matched reported growth companywide despite currency effects and the Kidney Care manufacturing and supply agreement.
Baxter's Segments Post Broad-Based Growth
Medical Products & Therapies
The segment includes the Infusion Therapies & Platforms and Advanced Surgery divisions. Sales in this segment totaled $2.08 billion, up 7% year over year on a reported basis and 5% organically. Growth was driven by strength in Drug Compounding and IV Solutions, along with continued solid global demand for Advanced Surgery products. The increase was partly offset by lower Infusion Systems sales due to the previously disclosed shipment and installation hold of the Novum IQ LVP, as well as weakness in Injectables.
Infusion Therapies & Platforms sales totaled $1.75 billion, up 6% year over year on a reported basis and 4% organically. Advanced Surgery revenues amounted to $331 million, up 12% on both a reported and organic basis. The division benefited from demand for hemostats and sealants, strong commercial execution across regions and steady procedure volumes.
Healthcare Systems & Technologies
The segment includes the Care & Connectivity Solutions and Front Line Care divisions. Total sales in this segment were $801 million, up 4% year over year on both a reported and organic basis. Growth reflected strong demand for Care & Connectivity Solutions products, led by Patient Support Systems, along with improvement in Front Line Care.
Care & Connectivity Solutions sales totaled $502 million, up 6% year over year on a reported basis and 5% organically. Performance benefited from higher Patient Support Systems volumes, execution against the U.S. backlog and growth across international markets. Front Line Care revenues were $299 million, up 2% on both a reported and organic basis, driven by Connex 360 momentum and the timing of large customer deals, partly offset by planned global product exits.
Baxter's Margins Remain Under Pressure
Adjusted gross profit was $1.14 billion, down 0.2% year over year. Adjusted gross margin contracted 210 basis points to 38.6%, reflecting the roll-through of higher-cost inventory produced at the end of 2025 and an unfavorable comparison tied to prior-year cost reclassification.
Selling, general and administrative expenses amounted to $735 million, up 2% year over year. Research and development expenses totaled $129 million, down 4%.
Adjusted operating income was $421 million, down 0.5% year over year. Adjusted operating margin contracted 90 basis points to 14.2%.
BAX's Cash Flow Supports Deleveraging
Cumulative net cash from operating activities at the end of second-quarter 2026 was $510 million compared with $118 million a year ago.
Management continues to target net leverage of about 3.0 times by the end of 2026 while maintaining an investment-grade credit rating. Near-term capital priorities remain debt repayment and organic investment in core platforms, innovation and productivity-enhancing projects.
Baxter Raises 2026 Outlook
Baxter raised its sales and adjusted earnings guidance for 2026.
Sales from continuing operations are now estimated to grow 3-4% on a reported basis, compared with the prior projection of flat to 1% growth. Organic sales growth is anticipated in the 2-3% range compared with the earlier expectation of approximately flat growth. The Zacks Consensus Estimate is pegged at $11.36 billion, implying 1% growth.
Adjusted EPS from continuing operations is now projected in the band of $1.95-$2.15, up from the previous range of $1.85-$2.05. Medical Products & Therapies and Healthcare Systems & Technologies are each expected to deliver low-single-digit organic growth. The Zacks Consensus Estimate for adjusted EPS is pegged at $1.91 per share.
Baxter International Inc. Price, Consensus and EPS Surprise
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
View the Zacks #1 Rank List
Image: Bigstock
BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract
Key Takeaways
Baxter International Inc. (BAX - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) from continuing operations of 56 cents, which topped the Zacks Consensus Estimate of 36 cents by 55.6%. The bottom line declined 5% from the year-ago quarter’s level.
On a GAAP basis, the company reported an EPS from continuing operations of 26 cents compared to an EPS of 24 cents in the prior-year quarter.
Shares of BAX gained 16.6% in pre-market trading. Year to date, the company’s shares have gained 29.6%, outperforming the industry’s fall of 16.1% and the broader S&P 500 Index’s increase of 6.7%.
Image Source: Zacks Investment Research
BAX's Revenue Mix Shows Broad-Based Gains
Revenues from continued operations totaled $2.96 billion, up 5% year over year on both a reported and organic basis. The top line surpassed the Zacks Consensus Estimate by 5.9%. Growth was driven by broad-based gains across Baxter’s segments and divisions.
U.S. sales from continuing operations totaled $1.59 billion, up 4% on both a reported and organic basis. International sales from continuing operations totaled $1.37 billion, reflecting an increase of 7% on a reported basis and 5% on an organic basis.
International growth outpaced the domestic business, while organic growth matched reported growth companywide despite currency effects and the Kidney Care manufacturing and supply agreement.
Baxter's Segments Post Broad-Based Growth
Medical Products & Therapies
The segment includes the Infusion Therapies & Platforms and Advanced Surgery divisions. Sales in this segment totaled $2.08 billion, up 7% year over year on a reported basis and 5% organically. Growth was driven by strength in Drug Compounding and IV Solutions, along with continued solid global demand for Advanced Surgery products. The increase was partly offset by lower Infusion Systems sales due to the previously disclosed shipment and installation hold of the Novum IQ LVP, as well as weakness in Injectables.
Infusion Therapies & Platforms sales totaled $1.75 billion, up 6% year over year on a reported basis and 4% organically. Advanced Surgery revenues amounted to $331 million, up 12% on both a reported and organic basis. The division benefited from demand for hemostats and sealants, strong commercial execution across regions and steady procedure volumes.
Healthcare Systems & Technologies
The segment includes the Care & Connectivity Solutions and Front Line Care divisions. Total sales in this segment were $801 million, up 4% year over year on both a reported and organic basis. Growth reflected strong demand for Care & Connectivity Solutions products, led by Patient Support Systems, along with improvement in Front Line Care.
Care & Connectivity Solutions sales totaled $502 million, up 6% year over year on a reported basis and 5% organically. Performance benefited from higher Patient Support Systems volumes, execution against the U.S. backlog and growth across international markets. Front Line Care revenues were $299 million, up 2% on both a reported and organic basis, driven by Connex 360 momentum and the timing of large customer deals, partly offset by planned global product exits.
Baxter's Margins Remain Under Pressure
Adjusted gross profit was $1.14 billion, down 0.2% year over year. Adjusted gross margin contracted 210 basis points to 38.6%, reflecting the roll-through of higher-cost inventory produced at the end of 2025 and an unfavorable comparison tied to prior-year cost reclassification.
Selling, general and administrative expenses amounted to $735 million, up 2% year over year. Research and development expenses totaled $129 million, down 4%.
Adjusted operating income was $421 million, down 0.5% year over year. Adjusted operating margin contracted 90 basis points to 14.2%.
BAX's Cash Flow Supports Deleveraging
Cumulative net cash from operating activities at the end of second-quarter 2026 was $510 million compared with $118 million a year ago.
Management continues to target net leverage of about 3.0 times by the end of 2026 while maintaining an investment-grade credit rating. Near-term capital priorities remain debt repayment and organic investment in core platforms, innovation and productivity-enhancing projects.
Baxter Raises 2026 Outlook
Baxter raised its sales and adjusted earnings guidance for 2026.
Sales from continuing operations are now estimated to grow 3-4% on a reported basis, compared with the prior projection of flat to 1% growth. Organic sales growth is anticipated in the 2-3% range compared with the earlier expectation of approximately flat growth. The Zacks Consensus Estimate is pegged at $11.36 billion, implying 1% growth.
Adjusted EPS from continuing operations is now projected in the band of $1.95-$2.15, up from the previous range of $1.85-$2.05. Medical Products & Therapies and Healthcare Systems & Technologies are each expected to deliver low-single-digit organic growth. The Zacks Consensus Estimate for adjusted EPS is pegged at $1.91 per share.
Baxter International Inc. Price, Consensus and EPS Surprise
Baxter International Inc. price-consensus-eps-surprise-chart | Baxter International Inc. Quote
BAX’s Zacks Rank & Stocks to Consider
Currently, Baxter carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.